4-(1H-benzoimidazol-2-ylsulfanyl)butyric acid ethyl ester | 74989-05-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-(1H-benzoimidazol-2-ylsulfanyl)butyric acid ethyl ester
• 英文别名: 4-(1H-benzoimidazol-2-ylsulfanyl)-butyric acid ethyl ester；4-(benzimidazole-2-ylthio)butanoate ethyl ester；ethyl 4-(benzimidazole-2-ylthio)butyrate；2-(ω-Carbaethoxybutylmercapto)benzimidazol；Ethyl 4-[(1H-benzimidazol-2-yl)sulfanyl]butanoate；ethyl 4-(1H-benzimidazol-2-ylsulfanyl)butanoate
• CAS: 74989-05-2
• 化学式: C₁₃H₁₆N₂O₂S
• 分子量: 264.348
• InChiKey: ZLLRWPQQYDNJQS-UHFFFAOYSA-N

物化性质

• 熔点：
  80 °C(Solv: hexane (110-54-3))
• 沸点：
  443.3±47.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  80.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (氯甲基)萘 、 4-(1H-benzoimidazol-2-ylsulfanyl)butyric acid ethyl ester 在 (氯甲基)萘 作用下， 以77的产率得到ethyl 4-(1-((1-naphthyl)methyl)benzimidazole-2-ylthio)butyrate
  参考文献：
  名称：

  Human chymase inhibitors

  摘要：

  本发明提供了一种由以下式子（1）表示的苯并咪唑衍生物或其药学上可接受的盐。此外，本发明提供了一种人类凝血酶活性抑制剂，其包含该物质作为活性成分。其中（A环表示吡啶环或苯环；X1和X2分别是氢原子、卤原子、三卤甲基基团、氰基、取代或未取代的烷基、取代或未取代的烷氧基等；B是取代或未取代的烷基、烷基烯基等；E是-COOR4等；G是取代或未取代的烷基烷基等；J是取代或未取代的烷基、取代或未取代的芳基等；M是硫原子、亚硫酸基、砜基或类似物）。

  公开号：

  US20030083315A1
• 作为产物：
  描述：

  4-溴丁酸乙酯 、 1H-苯并咪唑-2-硫醇 在 potassium carbonate 作用下， 以 乙醇 为溶剂， 以81%的产率得到4-(1H-benzoimidazol-2-ylsulfanyl)butyric acid ethyl ester
  参考文献：
  名称：

  合成2-硫代苯并咪唑衍生物作为潜在的抗丝虫剂

  摘要：

  几种5-苯甲酰基-2-硫代苯并咪唑和2-硫代苯并咪唑的脂族酸，酯，N，N-二烷基甲酰胺和硫代羧酰胺是通过使溴代脂肪酸，溴代脂族酸酯和N，N-二烷基氨基甲酰基或硫代氨基甲酰氯与5在碱存在下的-苯甲酰基-2-硫代苯并咪唑或2-硫代苯并咪唑 在碱存在下，通过2-硫代苯并咪唑与氯甲酸甲酯或氯甲酸乙酯反应，制得2-硫代羰基甲氧基-和2-硫代羰基乙氧基苯并咪唑。但是，使5-苯甲酰基-2-硫代苯并咪唑与氯甲酸乙酯反应，得到5-苯甲酰基-2-乙基硫代苯并咪唑。

  DOI：

  10.1002/jhet.5570220525

文献信息

• Benzimidazole derivatives
  申请人：——

  公开号：US20040010004A1

  公开（公告）日：2004-01-15

  A benzimidazole derivative or its medically acceptable salt, represented by the following formula (1), that is a human chymase activity inhibitor capable of being applied clinically: 1 wherein, R 1 and R 2 represent a hydrogen atom, an alkyl group or an alkoxy group, etc., A represents an alkylene group or an alkenylene group, E represents —COOR 3 , —SO 3 R 3 , —CONHR 3 or —SO 2 NHR 3 , etc., G represents an alkylene group, M represents a single bond or —S(O) m . J represents a heterocyclic group, and X represents —CH═ or a nitrogen atom.

  一种苯并咪唑衍生物或其医学上可接受的盐，由以下式（1）表示，该物质是一种人类凝血酶酶抑制剂，可在临床上应用：其中，R1和R2代表氢原子、烷基或烷氧基等，A代表烷基或烯烃基，E代表—COOR3、—SO3R3、—CONHR3或—SO2NHR3等，G代表烷基，M代表单键或—S(O)m。J代表杂环基，X代表—CH或氮原子。
• Benzimidazole derivative
  申请人：Tsuchiya Naoki

  公开号：US20050267148A1

  公开（公告）日：2005-12-01

  The present invention is a thiobenzimidazole derivative represented by the following formula (1) or a medically acceptable salt thereof wherein said thiobenzimidazole derivative and a medically acceptable salt thereof have a potent activity of inhibiting human chymase. Thus, they are potential preventive and/or therapeutic agents clinically applicable to various diseases in which human chymase is involved.

  本发明是一种由以下式（1）表示的硫苯并咪唑衍生物或其医学上可接受的盐，其中所述的硫苯并咪唑衍生物及其医学上可接受的盐具有抑制人体胰蛋白酶的强效活性。因此，它们是潜在的预防和/或治疗剂，可在涉及人体胰蛋白酶的各种疾病中进行临床应用。
• Noval benzimidazole and azabenzimiazole derivatives which are
  申请人：Laboratoires UPSA

  公开号：US05021443A1

  公开（公告）日：1991-06-04

  The present invention relates to the derivatives of the formula ##STR1## in which: A is an aromatic ring or a nitrogen heterocycle; X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are independently a hydrogen atom, a halogen atom, a lower alkyl radical, an alkoxy radical, an alkylthio radical, a sulfone group, a sulfoxide group, a trifluoromethyl group, a nitro group, a hydroxyl group, a methylene alcohol radical or a group COOR', in which R' is a hydrogen or a lower alkyl; X.sub.3 and X.sub.4 can also form a naphthalene with the phenyl; B is CR.sub.5 R.sub.6, R.sub.5 and R.sub.6 being a hydrogen atom or a lower alkyl, or the sulfur atom; R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom or a lower alkyl radical; CR.sub.1 R.sub.2 or CR.sub.3 R.sub.4 can form with B, when the latter is CR.sub.5 R.sub.6, a cycloalkyl or a cycloalkene having 3 to 7 carbon atoms; R.sub.1 R.sub.2 and R.sub.3 R.sub.4 can also form a ring having 3 to 6 carbon atoms; n is an integer from 1 to 4 and can be 0 if R.sub.1 and R.sub.2 are other than hydrogen; and D is a chemical group which can be: COOR.sub.7, R.sub.7 being the hydrogen atom or a lower alkyl, CONH--R.sub.8, R.sub.8 being the hydrogen atom or a lower alkyl, CN, ##STR2## R.sub.9 being the hydrogen atom or a lower alkyl, or NHSO.sub.2 CF.sub.3, and to their addition salts.

  本发明涉及公式##STR1##的衍生物，其中：A是芳香环或氮杂环；X.sub.1、X.sub.2、X.sub.3和X.sub.4分别是氢原子、卤素原子、低碳基基团、烷氧基团、烷硫基团、磺酰基、亚磺酰基、三氟甲基基团、硝基、羟基、甲基醇基团或COOR'基团，其中R'是氢或低碳基；X.sub.3和X.sub.4还可以与苯环形成萘环；B是CR.sub.5R.sub.6，R.sub.5和R.sub.6是氢原子或低碳基团，或硫原子；R.sub.1、R.sub.2、R.sub.3和R.sub.4分别是氢原子或低碳基基团；当B是CR.sub.5R.sub.6时，CR.sub.1R.sub.2或CR.sub.3R.sub.4可以与B形成有3到7个碳原子的环烷基或环烯基；R.sub.1R.sub.2和R.sub.3R.sub.4还可以形成有3到6个碳原子的环；n是1到4的整数，如果R.sub.1和R.sub.2不是氢，则可以为0；D是一种化学基团，可以是：COOR.sub.7，其中R.sub.7是氢原子或低碳基团，CONH--R.sub.8，其中R.sub.8是氢原子或低碳基团，CN，##STR2##其中R.sub.9是氢原子或低碳基团，或NHSO.sub.2CF.sub.3，以及其加合盐。
• Benzimidazole and azabenzimidazole derivatives which are thromboxane
  申请人：Laboratoires UPSA

  公开号：US05128359A1

  公开（公告）日：1992-07-07

  The present invention relates to the derivatives of the formula ##STR1## where the substituents are defined in the specification. These compounds possess thromboxane receptor antagonist properties.

  本发明涉及公式为##STR1##的衍生物，其中取代基在规范中定义。这些化合物具有血栓素受体拮抗剂的性质。
• Azabenzimidazole derivatives which are thromboxane receptor antagonists
  申请人：Laboratoires UPSA

  公开号：US05124336A1

  公开（公告）日：1992-06-23

  The present invention relates to the derivatives of the formula ##STR1## in which: A is an aromatic ring or a nitrogen heterocycle; X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are independently a hydrogen atom, a halogen atom, a lower alkyl radical, a C.sub.3 -C.sub.7 cycloalkyl radical, an alkoxy radical, an alkylthio radical, a sulfone group, SO.sub.2 -lower alkyl, a sulfoxide group, SO-lower alkyl, a trifluoromethyl group, a nitro group, a hydroxyl group, a methylene alcohol radical or a group COOR', in which R' is a hydrogen or a lower alkyl; X.sub.3 and X.sub.4 can also form a naphthalene with the phenyl; B is CR.sub.5 R.sub.6, R.sub.5 and R.sub.6 being a hydrogen atom, a lower alkyl or a C.sub.3 -C.sub.7 cycloalkyl radical, or the sulfur atom; R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom, a lower alkyl radical or a C.sub.3 -C.sub.7 cycloalkyl radical; CR.sub.1 R.sub.2 or CR.sub.3 R.sub.4 can form with B, when the latter is CR.sub.5 R.sub.6, a cycloalkyl or a cycloalkene having 3 to 7 carbon atoms; R.sub.1 R.sub.2 and R.sub.3 R.sub.4 can also form a ring having 3 to 7 carbon atoms; n is an integer from 1 to 4 and can be 0 if R.sub.1 and R.sub.2 are other than hydrogen; and D is a chemical group which can be: COOR.sub.7, R.sub.7 being the hydrogen atom, a lower alky radical or a C.sub.3 -C.sub.7 cycloalkyl radical, CONH-R.sub.8, R.sub.8 being the hydrogen atom, a lower alkyl radical or a C.sub.3 -C.sub.7 cycloalkyl radical, or CN, and to their addition salts. The compounds are thromboxane antagonist receptors.

  本发明涉及公式##STR1##的衍生物，其中：A是芳香环或氮杂环；X.sub.1、X.sub.2、X.sub.3和X.sub.4独立地是氢原子、卤素原子、较低的烷基基团、C.sub.3-C.sub.7环烷基基团、烷氧基、烷基硫基、磺酰基、SO.sub.2-较低烷基、亚磺酰基、SO-较低烷基、三氟甲基基团、硝基、羟基、亚甲基醇基团或COOR'基团，其中R'是氢或较低的烷基；X.sub.3和X.sub.4还可以与苯环形成萘环；B是CR.sub.5R.sub.6，R.sub.5和R.sub.6是氢原子、较低的烷基或C.sub.3-C.sub.7环烷基基团，或硫原子；R.sub.1、R.sub.2、R.sub.3和R.sub.4独立地是氢原子、较低的烷基基团或C.sub.3-C.sub.7环烷基基团；当B为CR.sub.5R.sub.6时，CR.sub.1R.sub.2或CR.sub.3R.sub.4可以与B形成具有3到7个碳原子的环烷基或环烯烃基；R.sub.1R.sub.2和R.sub.3R.sub.4也可以形成具有3到7个碳原子的环；n是1到4的整数，如果R.sub.1和R.sub.2不是氢，则可以为0；D是一个化学基团，可以是：COOR.sub.7，其中R.sub.7是氢原子、较低的烷基或C.sub.3-C.sub.7环烷基基团，CONH-R.sub.8，其中R.sub.8是氢原子、较低的烷基或C.sub.3-C.sub.7环烷基基团，或CN，以及它们的加成盐。这些化合物是血栓素拮抗受体。